The CDC estimates 46.2 million Adults in the US Smoke Cigarettes and that 70% of those Smokers Have a Desire to Quit, Representing a Large Potential Market for Smoking Cessation Products.
DUBLIN, Irelalnd -- Research and Markets (http://www.researchandmarkets.com/reports/c31650) has announced the addition of Opportunities in the Pharmacotherapy pharmacotherapy /phar·ma·co·ther·a·py/ (-ther´ah-pe) treatment of disease with medicines.
Treatment of disease through the use of drugs. of Addiction to their offering.
In 2003, almost 18 million people in the United States abused or were dependent on alcohol, and almost 20 million were illicit drug users. Many people abuse both alcohol and drugs. But the single most common avoidable cause of morbidity and mortality Morbidity and Mortality can refer to:
CDC - Control Data Corporation ). The CDC estimates that 46.2 million adults in the United States smoke cigarettes and that 70% of those smokers have a desire to quit, representing a large potential market for smoking cessation products.
This report provides an overview of substance abuse and dependency and reviews current and emerging therapies for the treatment of addiction to alcohol, illicit drugs, and nicotine. In conclusion, it forecasts changes in the market that will increase opportunities for companies that develop pharmacotherapeutic treatments for addiction.
Although addiction to alcohol and illicit drugs is a significant problem that costs society hundreds of billions of dollars each year, only a limited number of treatments are available to address this problem. Until 2004, only two drugs (disulfiram disulfiram /di·sul·fi·ram/ (di-sul´fi-ram) an antioxidant that inhibits the oxidation of the acetaldehyde metabolized from alcohol, resulting in high concentrations of acetaldehyde in the body. (Odyssey Pharmaceuticals' Antabuse) and naltrexone naltrexone /nal·trex·one/ (nal-trek´son) an opioid antagonist used as the hydrochloride salt in treatment of opioid or alcohol abuse.
An endorphin and narcotic antagonist. (Barr Pharmaceuticals' ReVia, generics)) were approved in the United States for treatment of alcohol dependence, and until 2002, only three drugs (methadone methadone (mĕth`ədōn', –dŏn'), synthetic narcotic similar in effect to morphine. Synthesized in Germany, it came into clinical use after World War II. It is sometimes used as an analgesic and to suppress the cough reflex. (Roxane Laboratories' Dolophine, generics), naltrexone, and levomethadyl (Roxane Laboratories' Orlaam)) were approved for treatment of opioid dependence; levomethadyl has since been pulled from the market.
The 2004 approval and 2005 market introduction of acamprosate calcium (Forest Laboratories Campral) for treatment of alcohol dependence and the 2002 introduction of buprenorphine and buprenorphone/naloxone (Reckitt Benckisers Subutex and Suboxone, respectively) for treatment of opioid dependence are representative of changes occurring in the market for drug and alcohol addiction. It is expected that the market will continue to grow but it is anticipated that expansion will be slow owing to several societal factors.
An estimated 46 million adults in the United States smoke cigarettes, and smoking claims more than 440,000 lives each year. Several products for smoking cessation are already available, including many over-the-counter and prescription products for nicotine replacement therapy Nicotine replacement therapy
A method of weaning a smoker away from both nicotine and the oral fixation that accompanies a smoking habit by giving the smoker smaller and smaller doses of nicotine in the form of a patch or gum. and the antidepressant antidepressant, any of a wide range of drugs used to treat psychic depression. They are given to elevate mood, counter suicidal thoughts, and increase the effectiveness of psychotherapy. bupropion bupropion /bu·pro·pi·on/ (bu-pro´pe-on) a monocyclic compound structurally similar to amphetamine, used as the hydrochloride salt as an antidepressant and as an aid in smoking cessation. (GlaxoSmithKlines Zyban).
It is forecast that the U.S. market for smoking cessation will continue to grow, fueled by the large percentage of smokers who have expressed a desire to quit. Significant need and market opportunity exist for a highly effective treatment, and additional non-nicotine products for smoking cessation have reached Phase III clinical trials, with more in earlier stages of development.
--Catalyst Pharmaceutical Partners
For more information visit http://www.researchandmarkets.com/reports/c31650